 | Up a level |
Lundgren, Jens D; Babiker, Abdel G; Sharma, Shweta; Grund, Birgit; Phillips, Andrew N; Matthews, Gail; Kan, Virginia L; Aagaard, Bitten; Abo, Inka; Alston, Beverly; Arenas-Pinto, Alejandro; Avihingsanon, Anchalee; Badal-Faesen, Sharlaa; Brites, Carlos; Carey, Cate; Casseb, Jorge; Clarke, Amanda; Collins, Simon; Corbelli, Giulio Maria; Dao, Sounkalo; ... (2023). Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection. NEJM Evidence, 2(3) NEJM Group 10.1056/evidoa2200302
Levi, Laura I; Sharma, Shweta; Schleiss, Mark R; Furrer, Hansjakob; Nixon, Daniel E; Blackstad, Mark; Hernandez-Alvarado, Nelmary; Dwyer, Dominic E; Borges, Alvaro H; Lane, H Clifford; Lundgren, Jens; Neaton, James D; Molina, Jean-Michel (2022). Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. AIDS, 36(9), pp. 1265-1272. Wolters Kluwer Health 10.1097/QAD.0000000000003238
Boatman, Jeffrey A; Baker, Jason V; Emery, Sean; Furrer, Hansjakob; Mushatt, David M; Sedlacek, Dalibor; Lundgren, Jens D; Neaton, James D (2019). Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm3: Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial. Journal of acquired immune deficiency syndromes JAIDS, 81(1), pp. 10-17. Wolters Kluwer Health 10.1097/QAI.0000000000001967
